ERN-EuroBloodNet clinical practice guidelines on Diagnosis and treatment of Burkitt lymphoma in adults has been published!
ERN-EuroBloodNet expert panel has reviewed recent advances in the management of Burkitt lymphoma in the first-line setting to develop updated evidence-based and expert opinion-based recommendations on the management of this disease.
Burkitt lymphoma is a rare lymphoma entity that represents less than 5% of adult lymphomas. Although prognosis has improved with dose-dense therapy, Burkitt lymphoma remains an area of clinical and biological research with specificities due to the high incidence of CNS involvement and tumour lysis syndrome in patients with a high tumour burden. Few consensus recommendations are available concerning diagnosis, treatment, and prognostic factors in adult patients.
ERN-EuroBloodNet launched an action in 2019 to produce the Clinical Practice Guidelines on the disease, being chared by Dr. Vincent Ribrag (Institut Gustave Roussy, France) and configured by ten clinicians and pathologists involved in the clinical management of Burkitt lymphoma from eight EU member states, including: Dr. Martine Chamuleau (Academic Medical Center Amsterdam), Prof. Dr. Dieter Hoelzer (University of Frankfurt), Prof. Dr. Charles Herbaux (CHU de Montpellier), Prof. Dr. Josep Maria Ribera (Germans Trias i Pujol), Prof. Dr. Jan Walewski (Maria Sklodowska-Curie National Research Institute of Oncology), Prof. Dr. Pier Luigi Zinzani (University of Bologna), Dr. Vincent Ribrag (Institut Gustav-Roussy), Judit Mészáros Jørgensen (Aarhus University Hospital), Dr. Clementine Sarkozy (Institut Gustav-Roussy). Moreover, Natacha Bolaños (ERN-EuroBloodNet ePAG and representative of Lymphoma Coalition) is the patient representative actively involved in the development of such Recommendations from the beginning.
The "Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet" has been now published! The guideline includes the revision of recent advances in the management of Burkitt lymphoma in the first-line setting to develop updated evidence-based and expert opinion-based recommendations on the management of this disease.
Together with providing current indications on diagnosis and risk-adapted first-line therapy, the Review contains specific recommendations for the identification and management of important complications of Burkitt lymphoma such as tumour lysis syndrome and CNS-oriented therapy, and recommendations for prognostic assessment to guide treatment. Finally, unresolved questions for Burkitt lymphoma are highlighted, including questions around genetics, imaging, and second-line therapies, along with patient perspective.
The Guideline has been developed with the support of the ERN Guidelines project (Tender Nº SANTE(2018/B3/030) "Servicio de Evaluación del Servicio Canario de la Salud/ Fundación Canaria Instituto de Investigación Sanitaria de Canarias (SESCS/FIISC)", who has also released the publication “Prognostic Factors for Survival in Adults With Burkitt Lymphoma: A Systematic Review” on behalf of ERN-EuroBloodNet group.
Congratulations to the team!
